Prostate Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Prostate Cancer stocks.

Prostate Cancer Stocks Recent News

Date Stock Title
Oct 31 AMGN Amgen 'Laser-Focused' On Its Weight-Loss Shot As New Rival Pfizer Follows, Says CFO
Oct 31 EXEL Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine
Oct 31 AMGN Amgen Q3 Earnings Beat, Sales In Line, Obesity Candidate in Focus
Oct 31 EXEL Exelixis price target raised to $36 from $33 at Piper Sandler
Oct 31 AMGN Amgen Inc (AMGN) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic Pipeline ...
Oct 31 AMGN Amgen Inc. (AMGN) Q3 2024 Earnings Call Transcript
Oct 31 AMGN Amgen Inc. 2024 Q3 - Results - Earnings Call Presentation
Oct 31 AMGN Amgen (AMGN) Q3 2024 Earnings Call Transcript
Oct 30 AMGN Amgen updates 2024 guidance with revenue and EPS ranges including consensus
Oct 30 AMGN Compared to Estimates, Amgen (AMGN) Q3 Earnings: A Look at Key Metrics
Oct 30 AMGN Amgen (AMGN) Beats Q3 Earnings Estimates
Oct 30 CRDF Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
Oct 30 AMGN Amgen in charts: Prolia, XGEVA sales gain, while Enbrel continues to wind down in Q3
Oct 30 AMGN Amgen: Q3 Earnings Snapshot
Oct 30 AMGN Amgen Non-GAAP EPS of $5.58 beats by $0.47, revenue of $8.5B in-line
Oct 30 AMGN Amgen posts higher profit, obesity data on track for late this year
Oct 30 AMGN AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS
Oct 30 EXEL Q3 2024 Exelixis Inc Earnings Call
Oct 30 EXEL Exelixis Beats on Q3 Earnings and Sales, Raises Annual Outlook
Oct 30 EXEL Exelixis Inc (EXEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Prostate Cancer

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other areas of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. In later stages, it can lead to difficulty urinating, blood in the urine or pain in the pelvis, back, or when urinating. A disease known as benign prostatic hyperplasia may produce similar symptoms. Other late symptoms may include feeling tired due to low levels of red blood cells.Factors that increase the risk of prostate cancer include older age, a family history of the disease, and race. About 99% of cases occur in males over the age of 50. Having a first-degree relative with the disease increases the risk two to threefold. In the United States, it is more common in the African American population than the White American population. Other factors that may be involved include a diet high in processed meat, red meat or milk products or low in certain vegetables. An association with gonorrhea has been found, but a reason for this relationship has not been identified. An increased risk is associated with the BRCA mutations. Prostate cancer is diagnosed by biopsy. Medical imaging may then be done to determine if the cancer has spread to other parts of the body.Prostate cancer screening is controversial. Prostate-specific antigen (PSA) testing increases cancer detection, but it is controversial regarding whether it improves outcomes. Informed decision making is recommended when it comes to screening among those 55 to 69 years old. Testing, if carried out, is more reasonable in those with a longer life expectancy. While 5α-reductase inhibitors appear to decrease low-grade cancer risk, they do not affect high-grade cancer risk and thus are not recommended for prevention. Supplementation with vitamins or minerals does not appear to affect the risk.Many cases are managed with active surveillance or watchful waiting. Other treatments may include a combination of surgery, radiation therapy, hormone therapy or chemotherapy. When it only occurs inside the prostate, it may be curable. In those in whom the disease has spread to the bones, pain medications, bisphosphonates and targeted therapy, among others, may be useful. Outcomes depend on a person's age and other health problems as well as how aggressive and extensive the cancer is. Most men with prostate cancer do not end up dying from the disease. The 5-year survival rate in the United States is 99%. Globally, it is the second most common type of cancer and the fifth leading cause of cancer-related death in men. In 2012, it occurred in 1.1 million men and caused 307,000 deaths. It was the most common cancer in males in 84 countries, occurring more commonly in the developed world. Rates have been increasing in the developing world. Detection increased significantly in the 1980s and 1990s in many areas due to increased PSA testing. Studies of males who died from unrelated causes have found prostate cancer in 30% to 70% of those over age 60.

Browse All Tags